mRNA: A promising platform for cancer immunotherapy
Year: 2023
Type: review
Abstract: Messenger RNA (mRNA) is now in the limelight as a powerful tool for treating various human diseases, especially malignant tumors, thanks to the remarkable clinical outcomes of mRNA vaccines using lipid nanoparticle technology during the COVID-19 pandemic. Recent promising preclinical and clinical results that epitomize the advancement in mRNA and nanoformulation-based delivery technologies have highlighted the tremendous potential of mRNA in cancer immunotherapy. mRNAs can be harnessed for cancer immunotherapy in forms of various therapeutic modalities, including cancer vaccines, adoptive T-cell therapies, therapeutic antibodies, and immunomodulatory proteins. This review provides a comprehensive overview of the current state and prospects of mRNA-based therapeutics, including numerous delivery and therapeutic strategies.
Source: Advanced Drug Delivery Reviews
Authors: Byoungjae Kong, Yelee Kim, Eun Hye Kim, Jung Soo Suk, Yoosoo Yang
Language: English
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: hybrid
Estimated APC paid: $5,150
Funders: National Research Foundation, Ministry of Science, ICT and Future Planning, Korea Institute of Science and Technology, National Research Foundation of Korea, Ministry of Science and ICT, South Korea, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, National Institute of Neurological Disorders and Stroke
OpenAlex ID: W4383311353